Loading…
← CockpitCompetitor Analysis › 300194.SZ Fuan Pharmaceutical (Group) Co., Ltd. Class AOpen in the cockpit ↗

Fuan Pharmaceutical (Group) Co., Ltd. Class A300194.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major
Momentum strong 64
Mkt cap
$612M
US dollars, full cap
Free float
92%
of shares outstanding
$/day
$7.18M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-3.9 pp
WACC 6.3%
Hurdle
+17 pp
Req g minus delivered
Close · CNYCN¥3.43
1D-1.7%
1W-5.8%
1M-10.2%
3M-14.2%
6M-13.6%
YTD-22.6%
1Y-25.1%
ATR %2.7%
52w lowhigh31.4% off high

What Fuan Pharmaceutical (Group) does

Employees: 2,988

Fuan Pharmaceutical (Group) at a glance

Size Fuan Pharmaceutical (Group) (300194.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $612M, the 3193rd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥3.43 on 18 Nov 2026.

Performance Over six months the shares fell 13.6%, against -29.3% for the median peer and -20.0% for the China market (cap-weighted) — 5th highest of 20 in its peer set.

Growth Revenue fell 3.4% over the last twelve months (peer median +4.6%); the operating margin is -1.2% (peer median 4.4%).

Valuation It trades at 2.4× enterprise value to sales against a peer median of 3.5× (6th cheapest of 15).

Price implies For today's price to make sense, revenue must grow about 11% a year for seven years (Req g). Recent delivered growth is -6%, so the hurdle is +17 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 3.9 points below its cost of capital (6.3% WACC).

Relative performance

70809010021 May 202621 Aug 202618 Nov 2026300194.SZ 86Peer median 71
Six months, rebased to 100: Fuan Pharmaceutical (Group) against the median of its 20 peers (local-currency closes).

Fuan Pharmaceutical (Group) financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥1.65BCN¥1.73BCN¥2.38BCN¥2.63BCN¥2.41B
Revenue growth—-27%-10%+9%—
Gross profitCN¥748MCN¥563MCN¥1.19BCN¥1.34BCN¥1.34B
EBITDAn/aCN¥246MCN¥424MCN¥382MCN¥278M
Net incomeCN¥34.7MCN¥77.0MCN¥280MCN¥232MCN¥205M
Free cash flowCN¥277MCN¥228MCN¥104MCN¥114M-CN¥43.2M
Capital expenditureCN¥101MCN¥108MCN¥242MCN¥216MCN¥383M
Total debtCN¥627MCN¥879MCN¥932MCN¥1.00BCN¥822M

Quarterly statements and history in the cockpit →

Fuan Pharmaceutical (Group) competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-60%-40%-20%0%+20%-50%0%+50%002940ORCHPHARMA6035674105002793185750OLMA301211DBV300233BCAX600976IMMX300878300147CGEM300194.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Fuan Pharmaceutical (Group) is the large dot.

Fundamentals: revenue growth against valuation

0%+500%+1,000%0×10×20×002940ORCHPHARMA6035674105002793185750301096ABUS3008784123300194.SZRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Fuan Pharmaceutical (Group) is the large dot.

Capital: growth delivered against growth the price implies

-20%0%+20%+40%-25%0%25%50%00294060356741050027931857503002333001474123300194.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Fuan Pharmaceutical (Group) is the large dot.

Fuan Pharmaceutical (Group) competitors and peer comparison

How Fuan Pharmaceutical (Group) compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Fuan Pharmaceutical (Group) against its 20 peers (data as of 18 Nov 2026)
Measure300194.SZPeer medianRank in peer set
1-month return-10.2%-11.8%10th highest of 20
6-month return-13.6%-29.3%5th highest of 20
Distance from 52-week high-31.4%-43.9%5th highest of 20
Revenue growth (TTM)-3.4%+4.6%4th lowest of 15
Operating margin-1.2%4.4%5th lowest of 14
EV / Sales2.4×3.5×6th cheapest of 15
Growth the price implies (Req g, 7 yrs)10.9%-0.6%3rd most demanding of 10
Growth delivered (Del g)-5.9%+2.1%4th lowest of 10
Hurdle (Req g minus delivered)+16.9 pp+8.1 pp4th most demanding of 10
ROIC minus cost of capital-3.9 pp-4.8 pp6th highest of 13

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Fuan Pharmaceutical (Group) 300194.SZChina$612M-14%-3%-1%2.4×10.9%-5.9%
Zhejiang Anglikang Pharmaceutical 002940.SZChina$612M-52%-13%10%3.3×10.1%+2.1%
Orchid Pharma ORCHPHARMA.NSIndia$613M+30%+11%0%6.1×n/an/a
HeiLongJiang ZBD Pharmaceutical 603567.SSChina$610M-39%-82%n/a25.1×9.1%-25.1%
TTY Biopharm 4105.TWOTaiwan$615M+10%+5%29%3.0×-8.7%+8.8%
Achieve Life Sciences QUITUnited States$609Mn/an/an/an/an/an/a
Luoxin Pharmaceuticals Group Stock 002793.SZChina$609M-26%-10%-9%2.0×-1.0%-17.9%
Chongkundang 185750.KSSouth Korea$609M-27%+6%4%0.5×-6.6%+5.4%
Olema Pharmaceuticals OLMAUnited States$619M-49%n/an/an/an/an/a
Hubei Biocause Heilen Pharmaceutical 301211.SZChina$619M-10%+13%4%5.3×n/an/a
DBV Technologies DBV.PAFrance$604M-46%n/an/an/an/an/a
Shandong Jincheng Pharmaceutical 300233.SZChina$604M-31%+2%4%1.2×-0.6%-1.6%
Hangzhou Bio-Sincerity Pharma-Tech 301096.SZChina$602M-38%+5%-30%7.5×n/an/a
Bicara Therapeutics BCAXUnited States$623M-54%n/an/an/an/an/a
JIANMIN PHARMACEUTICAL 600976.SSChina$598M-14%-2%8%0.9×-6.2%+6.5%
Immix Biopharma IMMXUnited States$596M-20%n/an/an/an/an/a
Arbutus Biopharma ABUSUnited States$630M-6%+1,143%80%1.6×n/an/a
Zhejiang Wecome Pharmaceutical 300878.SZChina$632M-18%+92%-41%16.9×n/an/a
Xiangxue Pharmaceutical 300147.SZChina$591M-41%+3%-39%3.7×50.4%-12.3%
Center Laboratories 4123.TWOTaiwan$639M-29%+14%9%12.8×36.3%+16.2%
Cullinan Therapeutics CGEMUnited States$585M-37%n/an/an/an/an/a

Questions

Which companies are Fuan Pharmaceutical (Group)'s closest peers?
The cockpit's peer set: Zhejiang Anglikang Pharmaceutical (002940.SZ), Orchid Pharma (ORCHPHARMA.NS), HeiLongJiang ZBD Pharmaceutical (603567.SS), TTY Biopharm (4105.TWO), Achieve Life Sciences (QUIT), Luoxin Pharmaceuticals Group Stock (002793.SZ), Chongkundang (185750.KS), Olema Pharmaceuticals (OLMA).
Is Fuan Pharmaceutical (Group) expensive compared with its peers?
On ev / sales it trades at 2.4× against a peer median of 3.5×, 6th cheapest of 15 in its peer set. For today's price to make sense, revenue must grow about 11% a year for seven years (Req g). Recent delivered growth is -6%, so the hurdle is +17 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Fuan Pharmaceutical (Group) stock performed?
Over six months to 18 Nov 2026 the shares returned -13.6% against -29.3% for the median peer; over one year -25.1%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.